Kura Oncology, Inc. (KURA) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -412.9%, revenue growth 25.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $67.48M |
| Revenue (TTM) | $0.1B |
| Net Margin | -412.9% |
| Operating Margin (TTM) | -408.2% |
| Net Debt / EBITDA | 0.2 |
| Revenue Growth (YoY) | 25.2% |
| EPS Growth (YoY) | 57.4% |
| FCF Growth (YoY) | -152.8% |
| Price / Book | 21.84 |
| Price / Sales | 13.53 |
| FCF Yield | -47.9% |
| Altman Z-Score | -1.41 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
KURA overview · KURA earnings · KURA KPIs · KURA documents · KURA ownership · KURA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.